US Biosimilars Take A Bite Out Of Roche's Herceptin, But Tecentriq Surges
Risdiplam Launch Among 2020 Tests
Roche's Q4 and full year results are slightly below expectations, but analysts still see it as one of sector's strong performers in 2020.
You may also be interested in...
CEO Vas Narasimhan is confident the Swiss major's gene therapy for spinal muscular atrophy will outperform present and future rivals – Biogen's Spinraza and Roche's risdiplam, respectively – as "we have a better profile simply because we are a one-time therapy."
Many clinicians doubt that aducanumab can really help slow the decline in Alzheimer’s patients – but US FDA could offer it the benefit of the doubt.
Timing means full EU approval could coincide with US FDA authorization later this year.